Loading company…
Tizona Therapeutics is a San Francisco biopharmaceutical company developing immunotherapies to improve cancer treatment.
Tizona develops immunotherapies intended to improve cancer treatment outcomes. Its lead product, TTX-080, is designed to enhance Cetuximab and chemotherapy for advanced colorectal cancer. The company works with healthcare providers and research institutions in North America and Europe. Founded in 2014 and headquartered in San Francisco, US, it saw Gilead Sciences, Inc. acquire a 49.9 percent stake for USD 300 mn in July 2020, with an option to acquire the remaining shares for an additional USD 1.25 bn.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in